Sandbox Reserved 687
From Proteopedia
Line 30: | Line 30: | ||
==[[Emtricitabine]] (ECT)== | ==[[Emtricitabine]] (ECT)== | ||
[[Image:Emtricitabine3.png]] | [[Image:Emtricitabine3.png]] | ||
- | <Structure load=' | + | <Structure load='ETV' size='500' frame='true' align='right' caption='[[Emtricitabine]] is an analog of cytidine and functions as antiretroviral drug (NRTI) for the treatment of HIV ' scene='Insert optional scene name here' /> |
Revision as of 20:52, 2 May 2013
This Sandbox is Reserved from 30/01/2013, through 30/12/2013 for use in the course "Biochemistry II" taught by Hannah Tims at the Messiah College. This reservation includes Sandbox Reserved 686 through Sandbox Reserved 700. |
To get started:
More help: Help:Editing |
Contents |
Complera: Emtricitabine/rilpivirine/tenofovir
- Marketed by: Gilead Sciences and Janssen Therapeutics
- Major Indication: HIV infection
- Drug Class: Combination of nucleoside/tide reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor
- Date of FDA Approval: August 2011
Upon infection, HIV binds to the CD4 receptor in a helper T cell or other CD4-presenting lymphocyte. The viral envelope is then fused with the cellular membrane allowing intracellular release of viral particles. The utilization of several enzymes helps to solidify the virus’s hold on the cell. HIV reverse transcriptase (RT) works to convert the viral single-stranded RNA (ssRNA) into DNA. HIV integrase then helps to incorporate the newly reverse transcribed DNA into the cellular genome. (Voet et al. 2008)
Rilpivirine (RPV)
|
RPV in the In red are the binding pocket residues p66 (Leu-100, Lys-101, Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu- 234, and Tyr-318) and p51(Glu-138). Singh et al.
Tenofovir (TFV)
|
Reverse Transcriptase:
Emtricitabine (ECT)
|